• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. J China Pharm Univ, 2024, 55(5): 590 − 602. DOI: 10.11665/j.issn.1000-5048.2024052202
Citation: YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. J China Pharm Univ, 2024, 55(5): 590 − 602. DOI: 10.11665/j.issn.1000-5048.2024052202
shu

Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system

  • Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

Funds: This study was supported by the National Natural Science Foundation of China (No. 82104097), the Natural Science Foundation of Jiangsu Province (BK20210426); and the Double First-Rate Construction Plan of China Pharmaceutical University (CPU2022QZ18)
More Information
  • Received Date: May 21, 2024
    Graphical Abstract
    • Abstract

  • The blood-brain barrier (BBB) is a semi-permeable biological barrier between brain tissue and plasma, however, its physical, enzymatic and immune properties, as well as its unique transport mechanism severely limit the entry of therapeutic drugs and diagnostic agents into the brain, which poses great challenges for the prevention and treatment of brain diseases. Hence, this review summarizes and discusses the complex structural components and various transport mechanisms of BBB, and interprets the difficulties and feasible ways of drug delivery across BBB. Furthermore, the latest research progress and future development trends of various delivery systems for brain drug delivery are introduced and discussed to provide references for further perfecting their design and driving their transformation. Finally, this review discusses the pathological changes of BBB in brain diseases and the design of drug delivery strategies for pathological BBB. Collectively, this review highlights the design and optimization of drug delivery strategies across the BBB based on nano-delivery system and provides accessible guide for current opportunities and challenges of intracerebral drug delivery.

    • FullText(HTML)
    • References (80)
  • [1]
    Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J]. Nat Rev Neurol, 2018, 14(3): 133-150.
    [2]
    Liebner S, Dijkhuizen RM, Reiss Y, et al. Functional morphology of the blood-brain barrier in health and disease[J]. Acta Neuropathol, 2018, 135(3): 311-336. doi: 10.1007/s00401-018-1815-1
    [3]
    Terstappen GC, Meyer AH, Bell RD, et al. Strategies for delivering therapeutics across the blood-brain barrier[J]. Nat Rev Drug Discov, 2021, 20(5): 362-383. doi: 10.1038/s41573-021-00139-y
    [4]
    Furtado D, Björnmalm M, Ayton S, et al. Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases[J]. Adv Mater, 2018, 30(46): e1801362. doi: 10.1002/adma.201801362
    [5]
    Ding SC, Khan AI, Cai XL, et al. Overcoming blood-brain barrier transport: advances in nanoparticle-based drug delivery strategies[J]. Mater Today, 2020, 37: 112-125. doi: 10.1016/j.mattod.2020.02.001
    [6]
    Zhou YT, Zhu FY, Liu Y, et al. Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer’s disease therapy[J]. Sci Adv, 2020, 6(41): eabc7031. doi: 10.1126/sciadv.abc7031
    [7]
    Jiang XY, Andjelkovic AV, Zhu L, et al. Blood-brain barrier dysfunction and recovery after ischemic stroke[J]. Prog Neurobiol, 2018, 163/164: 144-171. doi: 10.1016/j.pneurobio.2017.10.001
    [8]
    Brown LS, Foster CG, Courtney JM, et al. Pericytes and neurovascular function in the healthy and diseased brain[J]. Front Cell Neurosci, 2019, 13: 282.
    [9]
    Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways[J]. Nat Neurosci, 2016, 19(6): 771-783. doi: 10.1038/nn.4288
    [10]
    Heithoff BP, George KK, Phares AN, et al. Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain[J]. Glia, 2021, 69(2): 436-472. doi: 10.1002/glia.23908
    [11]
    Agrawal M, Saraf S, Saraf S, et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting[J]. J Control Release, 2020, 321: 372-415. doi: 10.1016/j.jconrel.2020.02.020
    [12]
    Cheng JM, Li JX, Duan XP. Applications of ferritin-based delivery system in biomedical field[J]. J China Pharm Univ (中国药科大学学报), 2024, 55(4): 530-537. doi: 10.1016/j.xphs.2017.04.036

    Cheng JM, Li JX, Duan XP. Applications of ferritin-based delivery system in biomedical field[J]. J China Pharm Univ (中国药科大学学报), 2024, 55(4): 530-537. doi: 10.1016/j.xphs.2017.04.036
    [13]
    Huang QQ, Jiang CQ, Xia X, et al. Pathological BBB crossing melanin-like nanoparticles as metal-ion chelators and neuroinflammation regulators against Alzheimer’s disease[J]. Research, 2023, 6: 0180. doi: 10.34133/research.0180
    [14]
    Luo Q, Lin YX, Yang PP, et al. A self-destructive nanosweeper that captures and clears amyloid β-peptides[J]. Nat Commun, 2018, 9(1): 1802. doi: 10.1038/s41467-018-04255-z
    [15]
    Song YH, De R, Lee KT. Emerging strategies to fabricate polymeric nanocarriers for enhanced drug delivery across blood-brain barrier: an overview[J]. Adv Colloid Interface Sci, 2023, 320: 103008. doi: 10.1016/j.cis.2023.103008
    [16]
    Kisler K, Nelson AR, Montagne A, et al. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease[J]. Nat Rev Neurosci, 2017, 18(7): 419-434. doi: 10.1038/nrn.2017.48
    [17]
    Longden TA, Dabertrand F, Koide M, et al. Capillary K+-sensing initiates retrograde hyperpolarization to increase local cerebral blood flow[J]. Nat Neurosci, 2017, 20(5): 717-726. doi: 10.1038/nn.4533
    [18]
    The intersection of bottom-up synthetic cell engineering and nanobiotechnology[J]. Nat Nanotechnol, 2024, 19(2): 131.
    [19]
    Kahana M, Weizman A, Gabay M, et al. Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson’s disease[J]. Mol Psychiatry, 2021, 26(6): 2626-2632. doi: 10.1038/s41380-020-0742-4
    [20]
    Sela M, Poley M, Mora-Raimundo P, et al. Brain-targeted liposomes loaded with monoclonal antibodies reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson’s disease[J]. Adv Mater, 2023, 35(51): e2304654. doi: 10.1002/adma.202304654
    [21]
    Ma FH, Yang L, Sun ZR, et al. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection[J]. Sci Adv, 2020, 6(30): eabb4429. doi: 10.1126/sciadv.abb4429
    [22]
    Rehman M, Madni A, Shi D, et al. Enhanced blood brain barrier permeability and glioblastoma cell targeting via thermoresponsive lipid nanoparticles[J]. Nanoscale, 2017, 9(40): 15434-15440. doi: 10.1039/C7NR05216B
    [23]
    Barbara R, Belletti D, Pederzoli F, et al. Novel curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Aβ aggregates[J]. Int J Pharm, 2017, 526(1/2): 413-424.
    [24]
    Dhar D, Ghosh S, Das S, et al. A review of recent advances in magnetic nanoparticle-based theranostics of glioblastoma[J]. Nanomed-Nanotechnol Biol Med, 2022, 17(2): 107-132.
    [25]
    He XQ, Xie J, Zhang J, et al. Acid-responsive dual-targeted nanoparticles encapsulated aspirin rescue the immune activation and phenotype in autism spectrum disorder[J]. Adv Sci, 2022, 9(14): e2104286. doi: 10.1002/advs.202104286
    [26]
    Ban JM, Li SD, Zhan Q, et al. PMPC modified PAMAM dendrimer enhances brain tumor-targeted drug delivery[J]. Macromol Biosci, 2021, 21(4): e2000392. doi: 10.1002/mabi.202000392
    [27]
    Yin Y, Wang J, Yang M, et al. Penetration of the blood-brain barrier and the anti-tumour effect of a novel PLGA-lysoGM1/DOX micelle drug delivery system[J]. Nanoscale, 2020, 12(5): 2946-2960. doi: 10.1039/C9NR08741A
    [28]
    Li YC, Xie MM, Jones JB, et al. Targeted delivery of DNA topoisomerase inhibitor SN38 to intracranial tumors of glioblastoma using sub-5 ultrafine iron oxide nanoparticles[J]. Adv Healthc Mater, 2022, 11(14): e2102816. doi: 10.1002/adhm.202102816
    [29]
    Cai J, Dao P, Chen HX, et al. Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: novel theranostic agents for Alzheimer’s disease[J]. Dyes Pigm, 2020, 173: 107968. doi: 10.1016/j.dyepig.2019.107968
    [30]
    Chung YJ, Lee BI, Park CB. Multifunctional carbon dots as a therapeutic nanoagent for modulating Cu(II)-mediated β-amyloid aggregation[J]. Nanoscale, 2019, 11(13): 6297-6306. doi: 10.1039/C9NR00473D
    [31]
    Ahlawat J, Guillama Barroso G, Masoudi Asil S, et al. Nanocarriers as potential drug delivery candidates for overcoming the blood-brain barrier: challenges and possibilities[J]. ACS Omega, 2020, 5(22): 12583-12595. doi: 10.1021/acsomega.0c01592
    [32]
    Li XQ, Vemireddy V, Cai Q, et al. Reversibly modulating the blood-brain barrier by laser stimulation of molecular-targeted nanoparticles[J]. Nano Lett, 2021, 21(22): 9805-9815. doi: 10.1021/acs.nanolett.1c02996
    [33]
    Dong CY, Huang QX, Cheng H, et al. Neisseria meningitidis opca protein/MnO2 hybrid nanoparticles for overcoming the blood-brain barrier to treat glioblastoma[J]. Adv Mater, 2022, 34(12): e2109213.
    [34]
    Gurudevan S, Kanwar RK, Veedu RN, et al. Targeted multimodal liposomes for nano-delivery and imaging: an avenger for drug resistance and cancer[J]. Curr Gene Ther, 2013, 13(5): 322-334. doi: 10.2174/156652321305131212123558
    [35]
    Gu WC, Luozhong SJ, Cai SM, et al. Extracellular vesicles incorporating retrovirus-like capsids for the enhanced packaging and systemic delivery of mRNA into neurons[J]. Nat Biomed Eng, 2024, 8(4): 415-426. doi: 10.1038/s41551-023-01150-x
    [36]
    Khan N, Shah FA, Rana I, et al. Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity[J]. Int J Pharm, 2020, 577: 119033. doi: 10.1016/j.ijpharm.2020.119033
    [37]
    Mojarad-Jabali S, Farshbaf M, Walker PR, et al. An update on actively targeted liposomes in advanced drug delivery to glioma[J]. Int J Pharm, 2021, 602: 120645. doi: 10.1016/j.ijpharm.2021.120645
    [38]
    Kong DH, Hong WY, Yu M, et al. Multifunctional targeting liposomes of epirubicin plus resveratrol improved therapeutic effect on brain gliomas[J]. Int J Nanomedicine, 2022, 17: 1087-1110. doi: 10.2147/IJN.S346948
    [39]
    Qu MK, Lin Q, He SS, et al. A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson’s disease[J]. J Control Release, 2018, 277: 173-182. doi: 10.1016/j.jconrel.2018.03.019
    [40]
    Hald Albertsen C, Kulkarni JA, Witzigmann D, et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy[J]. Adv Drug Deliv Rev, 2022, 188: 114416. doi: 10.1016/j.addr.2022.114416
    [41]
    Sun D, Lu ZR. Structure and function of cationic and ionizable lipids for nucleic acid delivery[J]. Pharm Res, 2023, 40(1): 27-46. doi: 10.1007/s11095-022-03460-2
    [42]
    Khare P, Edgecomb SX, Hamadani CM, et al. Lipid nanoparticle-mediated drug delivery to the brain[J]. Adv Drug Deliv Rev, 2023, 197: 114861. doi: 10.1016/j.addr.2023.114861
    [43]
    Liu SH, Liu J, Li HS, et al. An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy[J]. Biomaterials, 2022, 287: 121645. doi: 10.1016/j.biomaterials.2022.121645
    [44]
    Khan AR, Yang XY, Fu MF, et al. Recent progress of drug nanoformulations targeting to brain[J]. J Control Release, 2018, 291: 37-64. doi: 10.1016/j.jconrel.2018.10.004
    [45]
    Zhou YQ, Peng ZL, Seven ES, et al. Crossing the blood-brain barrier with nanoparticles[J]. J Control Release, 2018, 270: 290-303. doi: 10.1016/j.jconrel.2017.12.015
    [46]
    Jose S, Juna BC, Cinu TA, et al. Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies[J]. Colloids Surf B Biointerfaces, 2016, 142: 307-314. doi: 10.1016/j.colsurfb.2016.02.026
    [47]
    Koffie RM, Farrar CT, Saidi LJ, et al. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging[J]. Proc Natl Acad Sci U S A, 2011, 108(46): 18837-18842. doi: 10.1073/pnas.1111405108
    [48]
    Li W, Qiu JH, Li XL, et al. BBB pathophysiology-independent delivery of siRNA in traumatic brain injury[J]. Sci Adv, 2021, 7(1): eabd6889. doi: 10.1126/sciadv.abd6889
    [49]
    Israel LL, Galstyan A, Holler E, et al. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain[J]. J Control Release, 2020, 320: 45-62. doi: 10.1016/j.jconrel.2020.01.009
    [50]
    Qiao RR, Jia QJ, Hüwel S, et al. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier[J]. ACS Nano, 2012, 6(4): 3304-3310. doi: 10.1021/nn300240p
    [51]
    Liu H, Zhang J, Chen X, et al. Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside[J]. Nanoscale, 2016, 8(15): 7808-7826. doi: 10.1039/C6NR00147E
    [52]
    Shen C, Wang XX, Zheng ZX, et al. Doxorubicin and indocyanine green loaded superparamagnetic iron oxide nanoparticles with PEGylated phospholipid coating for magnetic resonance with fluorescence imaging and chemotherapy of glioma[J]. Int J Nanomedicine, 2019, 14: 101-117.
    [53]
    Peng YM, Zhan MS, Karpus A, et al. Brain delivery of biomimetic phosphorus dendrimer/antibody nano complexes for enhanced glioma immunotherapy via immune modulation of T cells and natural killer cells[J]. ACS Nano, 2024, 18(14): 10142-10155. doi: 10.1021/acsnano.3c13088
    [54]
    Wakaskar RR. General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes[J]. J Drug Target, 2018, 26(4): 311-318. doi: 10.1080/1061186X.2017.1367006
    [55]
    Teng YM, Jin HQ, Nan D, et al. In vivo evaluation of urokinase-loaded hollow nanogels for sonothrombolysis on suture embolization-induced acute ischemic stroke rat model[J]. Bioact Mater, 2017, 3(1): 102-109.
    [56]
    Hou K, Zhao J, Wang H, et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease[J]. Nat Commun, 2020, 11(1): 4790. doi: 10.1038/s41467-020-18525-2
    [57]
    Abla KK, Mehanna MM. The battle of lipid-based nanocarriers against blood-brain barrier: a critical review[J]. J Drug Target, 2023, 31(8): 832-857. doi: 10.1080/1061186X.2023.2247583
    [58]
    Mu Y,Zhao HM,Liu HC,et al.Advances in drug development for Alzheimer’s disease [J/OL].J China Pharm Univ (中国药科大学学报). [2024-08-25].https://link.cnki.net/urlid/32.1157.R.20240528.1404.006.

    Mu Y, Zhao HM, Liu HC,et al.Advances in drug development for Alzheimer’s disease [J/OL]．J China Pharm Univ (中国药科大学学报). [2024-08-25].https://link.cnki.net/urlid/32.1157.R.20240528.1404.006.
    [59]
    Zha S, Liu HT, Li HD, et al. Functionalized nanomaterials capable of crossing the blood-brain barrier[J]. ACS Nano, 2024, 18(3): 1820-1845. doi: 10.1021/acsnano.3c10674
    [60]
    Farfara D, Sooliman M, Avrahami L, et al. Physiological expression of mutated TAU impaired astrocyte activity and exacerbates β-amyloid pathology in 5xFAD mice[J]. J Neuroinflammation, 2023, 20(1): 174. doi: 10.1186/s12974-023-02823-9
    [61]
    Martins PAT, Alsaiari S, Julfakyan K, et al. Self-assembled lipoprotein based gold nanoparticles for detection and photothermal disaggregation of β-amyloid aggregates[J]. Chem Commun, 2017, 53(13): 2102-2105. doi: 10.1039/C6CC09085K
    [62]
    Liu YL, Ai KL, Ji XY, et al. Comprehensive insights into the multi-antioxidative mechanisms of melanin nanoparticles and their application to protect brain from injury in ischemic stroke[J]. J Am Chem Soc, 2017, 139(2): 856-862. doi: 10.1021/jacs.6b11013
    [63]
    Nitzsche F, Müller C, Lukomska B, et al. Concise review: MSC adhesion cascade-insights into homing and transendothelial migration[J]. Stem Cells, 2017, 35(6): 1446-1460. doi: 10.1002/stem.2614
    [64]
    Jin Y, Tang ZY, Shang S, et al. A nanodisc-paved biobridge facilitates stem cell membrane fusogenicity for intracerebral shuttling and bystander effects[J]. Adv Mater, 2023, 35(40): e2302367. doi: 10.1002/adma.202302367
    [65]
    Cheng GW, Liu YJ, Ma R, et al. Anti-parkinsonian therapy: strategies for crossing the blood-brain barrier and nano-biological effects of nanomaterials[J]. Nanomicro Lett, 2022, 14(1): 105.
    [66]
    de Rus Jacquet A, Alpaugh M, Denis HL, et al. The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson’s disease[J]. Nat Commun, 2023, 14(1): 3651. doi: 10.1038/s41467-023-39038-8
    [67]
    Paul G, Elabi OF. Microvascular changes in Parkinson’s disease- focus on the neurovascular unit[J]. Front Aging Neurosci, 2022, 14: 853372. doi: 10.3389/fnagi.2022.853372
    [68]
    da Rocha Lindner G, Bonfanti Santos D, Colle D, et al. Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism[J]. Nanomed-Nanotechnol Biol Med, 2015, 10(7): 1127-1138.
    [69]
    Kumar A, Chaudhary RK, Singh R, et al. Nanotheranostic applications for detection and targeting neurodegenerative diseases[J]. Front Neurosci, 2020, 14: 305. doi: 10.3389/fnins.2020.00305
    [70]
    Huang FY, Chen WJ, Lee WY, et al. In vitro and in vivo evaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery[J]. Int J Mol Sci, 2013, 14(2): 2862-2874.
    [71]
    Katila N, Duwa R, Bhurtel S, et al. Enhancement of blood-brain barrier penetration and the neuroprotective effect of resveratrol[J]. J Control Release, 2022, 346: 1-19. doi: 10.1016/j.jconrel.2022.04.003
    [72]
    El-Agnaf O, Overk C, Rockenstein E, et al. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy[J]. Neurobiol Dis, 2017, 104: 85-96. doi: 10.1016/j.nbd.2017.05.002
    [73]
    Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target[J]. Sci Transl Med, 2011, 3(84): 84ra44.
    [74]
    Sim HW, Morgan ER, Mason WP. Contemporary management of high-grade gliomas[J]. CNS Oncol, 2018, 7(1): 51-65. doi: 10.2217/cns-2017-0026
    [75]
    Sarkaria JN, Hu LS, Parney IF, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data[J]. Neuro Oncol, 2018, 20(2): 184-191. doi: 10.1093/neuonc/nox175
    [76]
    Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases[J]. Nat Rev Cancer, 2020, 20(1): 26-41. doi: 10.1038/s41568-019-0205-x
    [77]
    Dubois LG, Campanati L, Righy C, et al. Gliomas and the vascular fragility of the blood brain barrier[J]. Front Cell Neurosci, 2014, 8: 418.
    [78]
    van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment[J]. Drug Resist Updat, 2015, 19: 1-12. doi: 10.1016/j.drup.2015.02.002
    [79]
    Ma XT, Aravind A, Pfister BJ, et al. Animal models of traumatic brain injury and assessment of injury severity[J]. Mol Neurobiol, 2019, 56(8): 5332-5345. doi: 10.1007/s12035-018-1454-5
    [80]
    Wang JJ, Ni QK, Wang YF, et al. Nanoscale drug delivery systems for controllable drug behaviors by multi-stage barrier penetration[J]. J Control Release, 2021, 331: 282-295. doi: 10.1016/j.jconrel.2020.08.045
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (1084) PDF downloads (161) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：285555

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return